Suppr超能文献

摘除眼球的葡萄膜黑色素瘤中的浸润性调节性T细胞。

Infiltrative T regulatory cells in enucleated uveal melanomas.

作者信息

Lagouros Evan, Salomao Diva, Thorland Erik, Hodge David O, Vile Richard, Pulido Jose S

机构信息

Departments of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Trans Am Ophthalmol Soc. 2009 Dec;107:223-8.

Abstract

PURPOSE

The role of T regulatory (Treg) cells in blunting immune response to cancer appears to be significant, but the presence of Treg cells in uveal melanoma has not been extensively examined. We therefore evaluated the presence of tumor-infiltrating Treg cells in uveal melanomas.

METHODS

A retrospective search of Mayo Clinic records from 2000 to 2005 was performed to identify cases of eyes enucleated as a consequence of uveal melanoma. Histologic examination included location of the tumor, presence of emissary canal invasion, direct sclera extension, extraocular extension, cell type and predominant cell type, mitotic figures per 40 high-power fields, lymphocytic tumor invasion, necrosis, microvascular pattern, and presence of CD3, CD4, CD25, and Foxp3cells. Factors obtained by chart review were also evaluated, including clinical size and ultrasound thickness of tumor before enucleation, patient age at time of enucleation, systemic evaluation for metastatic disease both before and after enucleation, monosomy 3, and systemic status at last patient visit.

RESULTS

Of 42 enucleated eyes, 17 (40.5 %) were found to have lymphocytic infiltrate and 5 (11.9%) were considered positive for the presence of Treg cells (CD3+CD4+CD25+Foxp3+ or CD3+CD4+CD25-Foxp3+). Thus 29.4% (5 of 17) of those with lymphocytic infiltates had Treg cells, and 4 of the 5 with Treg cells had a large lymphocytic infiltrate (>1400 CD3 cells). When using "death due to disease" as the hazard ratio (HR) end point, the HR for presence of CD3 was 5.5 (P = .03) and for clinical size, 1.2 (P = .03). Furthermore, when using "presence of metastasis" as the end point, the HR for presence of CD3 was 3.6 (P = .05) and for clinical size, 1.3 (P = .003).

CONCLUSION

Though T lymphocyte infiltration is a bad prognostic indicator, Treg cells are rarely seen in enucleated choroidal melanoma, so their local effect may be limited in contradistinction to other cancers.

摘要

目的

调节性T(Treg)细胞在减弱对癌症的免疫反应中所起的作用似乎很重要,但葡萄膜黑色素瘤中Treg细胞的存在尚未得到广泛研究。因此,我们评估了葡萄膜黑色素瘤中肿瘤浸润性Treg细胞的存在情况。

方法

对梅奥诊所2000年至2005年的记录进行回顾性检索,以确定因葡萄膜黑色素瘤而摘除眼球的病例。组织学检查包括肿瘤的位置、有无引流管浸润、直接巩膜扩展、眼外扩展、细胞类型和主要细胞类型、每40个高倍视野中的有丝分裂象、淋巴细胞肿瘤浸润、坏死、微血管模式以及CD3、CD4、CD25和Foxp3细胞的存在情况。还评估了通过病历审查获得的因素,包括摘除眼球前肿瘤的临床大小和超声厚度、摘除眼球时患者的年龄、摘除眼球前后的转移性疾病全身评估、三体性3以及最后一次患者就诊时的全身状况。

结果

在42只摘除的眼球中,17只(40.5%)有淋巴细胞浸润,5只(11.9%)被认为存在Treg细胞(CD3+CD4+CD25+Foxp3+或CD3+CD4+CD25-Foxp3+)呈阳性。因此,在有淋巴细胞浸润的患者中,29.4%(17例中的5例)有Treg细胞,在5例有Treg细胞的患者中,有4例有大量淋巴细胞浸润(>1400个CD3细胞)。以“疾病导致的死亡”作为风险比(HR)终点时,CD3存在的HR为5.5(P = 0.03),临床大小的HR为1.2(P = 0.03)。此外,以“转移的存在”作为终点时,CD3存在的HR为3.6(P = 0.05),临床大小的HR为1.3(P = 0.003)。

结论

虽然T淋巴细胞浸润是一个不良预后指标,但在摘除的脉络膜黑色素瘤中很少见到Treg细胞,因此与其他癌症相比,它们的局部作用可能有限。

相似文献

1
Infiltrative T regulatory cells in enucleated uveal melanomas.
Trans Am Ophthalmol Soc. 2009 Dec;107:223-8.
2
Analysis of inflammatory cells in uveal melanoma after prior irradiation.
Invest Ophthalmol Vis Sci. 2013 Jan 14;54(1):360-9. doi: 10.1167/iovs.12-9424.
3
Prognostic Factors Five Years After Enucleation for Uveal Melanoma.
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):31. doi: 10.1167/iovs.61.3.31.
5
Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability.
Ophthalmology. 2008 Oct;115(10):1778-85. doi: 10.1016/j.ophtha.2008.04.025. Epub 2008 Jun 13.
7
Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?
Ophthalmology. 2010 Feb;117(2):334-42. doi: 10.1016/j.ophtha.2009.06.057. Epub 2009 Nov 4.
8
Traumatic enucleation for posterior uveal melanoma.
Am J Ophthalmol. 1990 Nov 15;110(5):518-21. doi: 10.1016/s0002-9394(14)77875-4.
9
Intraocular melanoma spread to regional lymph nodes: report of two cases.
Retina. 2000;20(1):76-9. doi: 10.1097/00006982-200001000-00014.
10
Diagnostic Cytologic Features of Uveal Melanoma.
Ophthalmology. 2015 Aug;122(8):1580-4. doi: 10.1016/j.ophtha.2015.04.013. Epub 2015 May 23.

引用本文的文献

1
Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model.
NPJ Syst Biol Appl. 2024 Sep 30;10(1):108. doi: 10.1038/s41540-024-00434-5.
2
The Phenotypical Characterization of Dual-Nature Hybrid Cells in Uveal Melanoma.
Cancers (Basel). 2024 Sep 22;16(18):3231. doi: 10.3390/cancers16183231.
3
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Curr Oncol. 2024 Feb 1;31(2):778-800. doi: 10.3390/curroncol31020058.
4
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
Br J Cancer. 2023 Sep;129(5):772-781. doi: 10.1038/s41416-023-02331-w. Epub 2023 Jul 13.
5
Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression.
J Immunol Res. 2021 Jun 11;2021:9920234. doi: 10.1155/2021/9920234. eCollection 2021.
6
Role of Natural Killer Cells in Uveal Melanoma.
Cancers (Basel). 2020 Dec 9;12(12):3694. doi: 10.3390/cancers12123694.
7
Update on uveal melanoma: Translational research from biology to clinical practice (Review).
Int J Oncol. 2020 Dec;57(6):1262-1279. doi: 10.3892/ijo.2020.5140. Epub 2020 Oct 22.
8
Uveal melanoma: progress in molecular biology and therapeutics.
Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852. doi: 10.1177/1758835920965852. eCollection 2020.
10
Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.
Front Oncol. 2019 Nov 5;9:1145. doi: 10.3389/fonc.2019.01145. eCollection 2019.

本文引用的文献

1
Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Med Hypotheses. 2008 Nov;71(5):802-4. doi: 10.1016/j.mehy.2008.06.022. Epub 2008 Aug 8.
2
Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling.
Gastroenterology. 2008 Oct;135(4):1333-43. doi: 10.1053/j.gastro.2008.06.042. Epub 2008 Jun 25.
3
Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation.
Immunity. 2008 Jul 18;29(1):114-26. doi: 10.1016/j.immuni.2008.05.010.
4
Malignant melanoma in the 21st century: the emerging molecular landscape.
Mayo Clin Proc. 2008 Jul;83(7):825-46. doi: 10.4065/83.7.825.
5
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.
Immunol Rev. 2008 Jun;223:371-90. doi: 10.1111/j.1600-065X.2008.00637.x.
6
Regulatory T cells: a new frontier in cancer immunotherapy.
Adv Exp Med Biol. 2008;622:255-60. doi: 10.1007/978-0-387-68969-2_20.
7
The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Gynecol Oncol. 2008 Aug;110(2):216-21. doi: 10.1016/j.ygyno.2008.04.021. Epub 2008 Jun 3.
8
The role of regulatory T cells in malignant glioma.
Anticancer Res. 2008 Mar-Apr;28(2B):1143-50.
9
Rethinking the molecular definition of regulatory T cells.
Eur J Immunol. 2008 Apr;38(4):928-30. doi: 10.1002/eji.200838147.
10
Immunoregulatory T cells: role and potential as a target in malignancy.
Curr Oncol Rep. 2008 Mar;10(2):130-6. doi: 10.1007/s11912-008-0021-z.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验